ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 389

ACR/EULAR Criteria for Myositis and Systemic Sclerosis Lack Sensitivity for Scleromyositis

Alain Meyer1, Valérie Leclair 2, Océane Landon-Cardinal 3, Benjamin Ellezam 4, Julie D'Aoust 5, Margherita Giannini 6, Bernard Geny 6, Laurent Arnaud 7, Jacques-Eric Gottenberg 8, Jean Sibilia 9, Minoru Satoh 10, Marvin Fritzler 11, Yves Troyanov 12 and Marie Hudson 13, 1Centre de Reference des Maladies Autoimmunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, 2Division of Rheumatology, Department of Medicine, Jewish General Hospital; Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Montreal, QC, Canada, 3Centre Hospitalier de l'Université de Montréal, Montréal, Canada, 4Department of Pathology, Centre Hospitalier Universitaire Sainte-Justine, Montréal, Canada, 5McGill University, Montreal, QC, Canada, 6CHU de Strasbourg, Strasbourg, France, 7Service de Rhumatologie, Centre National de Référence des Maladies Autoimmunes Systemiques Rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Strasbourg, France, 8Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 9CHU Strasbourg, Strasbourg, France, 10Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, 11Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 12Division of Rheumatology, Department of Medicine, Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, 13Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: classification criteria and autoantibodies, Idiopathic Inflammatory Myopathies (IIM), Myositis, Systemic sclerosis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 10, 2019

Session Title: Muscle Biology, Myositis & Myopathies Poster I

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Autoimmune myositis consists of a group of diseases with heterogeneous muscular and systemic manifestations. Prognosis also varies widely across the spectrum. Thus, myositis subgroups are being identified to facilitate personalized care. Systemic sclerosis (SSc) is a disease characterized by vasculopathy, autoimmunity, inflammation and fibrosis affecting multiple organs including muscle. The association of myositis and SSc is referred to as “scleromyositis”. Classification criteria for both myositis and SSc have been endorsed by ACR/EULAR but their performance for scleromyositis is unknown.

Methods: Patients with scleromyositis were identified in two centers. Diagnosis of scleromyositis was based on the co-existence of myositis and features of SSc according to expert opinion. Patients were systematically assessed for the presence or absence of items in the 2017 ACR/EULAR criteria for myositis and 2013 ACR/EULAR criteria for SSc at last follow-up. Additional organ involvement and auto-antibodies associated with myositis and SSc were also systematically recorded.

Results: Seventy (70) patients with scleromyositis (sex ratio F/M 3.7) were included. Age at myositis onset was 51.5 ± 15.8 years. Only 39 (56%) patients fulfilled the 2017 ACR/EULAR criteria for myositis (21 definite, 14 probable, 4 possible) and 53 patients (76%) fulfilled the 2013 ACR/EULAR criteria for SSc (Figure 1). Of these, only 29 (41%) fulfilled both sets of criteria. Seven (10%) patients fulfilled neither set of criteria (Figure 1a).   The ACR/EULAR criteria that were most frequently lacking for myositis were anti-Jo1 antibodies (n=70, 100%) and dermatomyositis rash (Gottron sign, Gottron papule and/or heliotrope rash n=61, 87%). The criteria that were most frequently lacking for SSc were pulmonary arterial hypertension (n=68, 97%) and “classical” SSc auto-antibodies (anti-Scl70, -centromere, -RNA polymerase III, n= 63, 90%).   The 7 patients fulfilling neither ACR/EULAR criteria for myositis nor SSc all had increased creatinine kinase and Raynaud’s phenomenon, but the frequency of the other items in the criteria were all < 50%. Four of the 7 patients (56%) had well-known complications of SSc some of which are not included in the criteria: interstitial lung disease (n=3), calcinosis (n=1) and/or renal crisis (n=1). All 7 patients had auto-antibodies associated with scleromyositis that are also not included in ACR/EULAR criteria: anti-Ku (n=3), anti-SMN1 (n=2), anti-PM/Scl (n=1), anti-U1RNP (n=1) and/or anti-RuvBL1/2 (n=1), When ACR/EULAR criteria for myositis and SSc were modified to take into account these additional clinical features and auto-antibodies, the rate of patients who fulfilled myositis and SSc criteria increased from 41% to 66% (Figure 1b).

Conclusion: In our cohort, ACR/EULAR criteria for myositis and SSc alone and together had low sensitivity for scleromyositis. Additional clinical features and serologies could lead to improved sensitivity.  Studies of scleromyositis will require careful consideration of inclusion criteria to ensure that the full spectrum of this important subset is included.


Disclosure: A. Meyer, None; V. Leclair, None; O. Landon-Cardinal, None; B. Ellezam, None; J. D'Aoust, None; M. Giannini, None; B. Geny, None; L. Arnaud, None; J. Gottenberg, Abbvie, 8, BMS, 2, 5, Lilly, 5, 8, Pfizer, 2, 5, Roche, 8, Sanofi-Genzyme, 5, 8, UCB, 5, 8; J. Sibilia, None; M. Satoh, None; M. Fritzler, Alexion Canada, 7, BioRad, 5, Dr. Fooke Laboratorien GmbH, 5, Euroimmun GmbH, 5, 7, ImmunoConcepts, 7, Inova Diagnostics, 5, 7, 8, Inova Diagnostics Inc. San diego, CA, 5, Inova Dx, Mikrogen GmbH, 5, Werfen International, 5; Y. Troyanov, None; M. Hudson, None.

To cite this abstract in AMA style:

Meyer A, Leclair V, Landon-Cardinal O, Ellezam B, D'Aoust J, Giannini M, Geny B, Arnaud L, Gottenberg J, Sibilia J, Satoh M, Fritzler M, Troyanov Y, Hudson M. ACR/EULAR Criteria for Myositis and Systemic Sclerosis Lack Sensitivity for Scleromyositis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/acr-eular-criteria-for-myositis-and-systemic-sclerosis-lack-sensitivity-for-scleromyositis/. Accessed January 26, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/acr-eular-criteria-for-myositis-and-systemic-sclerosis-lack-sensitivity-for-scleromyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.